PDC Therapeutics is a clinical-stage biotech start-up developing targeted Polymer-Drug Conjugate technologies with an optimal therapeutic index. The proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability.
Products, services, technology
Our Sagitta® nanocarriers are compatible with a broad spectrum of technology platforms used in conjugated drugs, including a wide range of targeting ligands/mAbs & linkers. Fine-tuning the selection of cleavable linkers enables controlled release of the payloads, improving the tolerability profile.
Cooperation possibilities
All Sagitta® nanocarrier platforms are available for licensing and co-development opportunities to enrich our partners' pipelines. Cooperating with multinational companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of experts.
- https://www.pdcbio.com
- Send an email
- Sena Nomak
Some insights
Many promising drug candidates fail to reach the clinic due to excessive toxicity and lack of efficacy. With the superior therapeutic index PDC Therapeutics is equipped to provide with its industry leading partners, patients will be able to reach next-gen therapies with no compromise.
The most advanced candidate utilizing Sagitta®, RS-0139 has reached patients via clinical trials and successfully continuing its phase-I with strong translation results. RS-0139 is developed by RS Research, which has a nanomedicine pipeline in various stages of preclinical and clinical development.
PDC Therapeutics was founded by EIC European Prize for Women Innovators 2024 winner Prof. Rana Sanyal and Sena Nomak. The company has a growing team of multidisciplinary specialists, supported by an industry-experienced board of scientific and supervisory experts around the world.
They think we work with magic molecules that fight cancer smarter than before, with science that sounds like science fiction. Probably something about polymers, payloads and making sure the medicine hits the bad guys without hurting the good ones. And that we’re never settling for less.
The Swiss biotech ecosystem can support us by fostering a vibrant space, enabling university-industry collaboration, Swissmedic guidance and access to cocreation opportunities backed by visionary investors, to push the boundaries of targeted therapies and help innovations reach patients.
We look forward to leveraging Sagitta® nanocarrier platforms to enrich the pipelines of our partners from pharma industry by developing cutting-edge solutions, connecting with strategic co-development partners and smart investors who share our commitment to targeted therapies with no compromise.